Effects of Kudiezi Injection on Serum Inflammatory Biomarkers in Patients with Acute Cerebral Infarction

Table 1

Baseline characteristic of the patients.

	Controls	KDZ
n	28	28
Age, mean (years)	62.0 ± 12.1	62.2 ± 16.0	0.963
Gender (F : M)	11 : 17	10 : 18	1.000
Risk factors, n (%)
Hypertension	15 (53.6)	17 (60.7)	0.787
Diabetes	9 (32.1)	9 (32.1)	1.000
Hypercholesterolemia	9 (32.1)	7 (25.0)	0.554
Dyslipidemia	9 (32.1)	7 (25.0)	0.768
Stroke history	6 (21.4)	4 (14.3)	0.729
Smoking	27 (96.4)	28 (100.0)	0.313
Complications, n (%)
Chronic kidney disease	1 (3.6)	2 (7.1)	1.000
Chronic lung disease	2 (7.1)	1 (3.6)	1.000
Coronary heart disease	5 (17.9)	3 (10.7)	0.705
Atrial fibrillation	1 (3.6)	1 (3.6)	1.000
Valvular heart disease/peripheral arterial disease	0/0	0/0	—
Stroke subtypes, n (%)
Large-artery atherosclerosis	3 (10.7)	1 (3.6)
Small blood vessel occlusion	12 (42.9)	14 (50.0)
Other or unknown causes	13 (46.4)	13 (46.4)